What is the market price of brigatinib/brigatinib tablets in 2024?

Brigatinib is a prescription drug developed to treat adults with non-small cell lung cancer (NSCLC), especially those who have a specific type of abnormal anaplastic lymphoma kinase (ALK) gene mutation and whose cancer has spread to other parts of the body. Currently, the medical community lacks sufficient data on the safety and efficacy of brigatinib in children. As a tyrosine kinase inhibitor, brigatinib exhibits inhibitory activity against multiple kinases, including ALK, ROS1, insulin-like growth factor-1 receptor, and even EGFR deletions and point mutations. Brigatinib can effectively inhibit the proliferation and in vitro survival of cells expressing the fusion protein EML4-ALK and 17 ALK mutant cells that are resistant to crizotinib.

It is worth mentioning that the original drug of brigatinib has been officially launched in the domestic market and has been included in the scope of Class B medical insurance drugs. The common packaging specifications on the market are diverse, such as 30mg 14 tablets in 2 plates, 90mg 7 tablets in 4 plates, 90mg 7 tablets and 180mg 7 tablets in 4 plates, etc. Nonetheless, the price tag for each box of medicines can be as high as about 10,000 yuan, which is undoubtedly a considerable expense for many patients. Fortunately, overseas markets offer more affordable generic options for brigatinib. These generic drugs are highly similar in composition to the original drugs sold domestically and abroad. For example, a box of 90mg 30-tablet generic drugs produced by a Bangladeshi pharmaceutical factory only costs about RMB 2,000 (note that the price may be adjusted due to exchange rate changes). This price advantage undoubtedly provides patients with more choices and financial relief.